Labcorp introduces the first US trimester preeclampsia screening test for all pregnant individuals.
Labcorp introduces the first trimester preeclampsia screening test to assess risk between 11-14 weeks gestation, making it the only test available in the US for all pregnant individuals. Preeclampsia, a high blood pressure disorder during pregnancy, affects roughly 1 in 25 US pregnancies and poses a greater risk for Black women. Labcorp's new test may help healthcare providers assess preeclampsia risk with objective biomarkers, potentially improving outcomes for mothers and their babies.
May 15, 2024
14 Articles